Drug Profile
REGN 1908 1909
Alternative Names: REGN-1908-1909Latest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; Sanofi
- Developer Regeneron Pharmaceuticals
- Class Allergy immunotherapies; Antiallergics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Allergic rhinitis
- Discontinued Hypersensitivity
Most Recent Events
- 25 Jun 2023 Phase-III clinical trials in Allergic rhinitis (In adults, In children, In adolescents) in US, Belgium, Poland, Germany, France, Canada (SC) (NCT04981717) (EudraCT2021-002089-42)
- 24 Feb 2023 Updated efficacy data from a phase II trial in Hypersensitivity presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology(AAAAI-2023)
- 06 Feb 2023 Discontinued - Phase-I/II for Hypersensitivity in United Kingdom, Sweden, New Zealand, Netherlands (SC) prior to February 2023